TP53 and osteosarcoma: Recently, we have demonstrated for the first time that RUNX2 attenuates p53 and/or TAp73-dependent cell death in p53-proficient osteosarcoma U2OS cells following DNA damage inducer adriamycin (ADR) exposure.47,48 In this study, we have focused on p53-deficient pancreatic cancer AsPC-1 cells and found that depletion of RUNX2 enhances the sensitivity to GEM of AsPC-1 cells in association with a significant stimulation of TAp63-dependent cell death pathway.